Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2016-12

AUTHORS

Hangping Wei, Fangming Du, Yifang Lu, Juan Wei, Xiaofang Dong

ABSTRACT

INTRODUCTION: Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor. It inhibits two of the most common ALK-mutants that confer resistance to crizotinib. Ceritinib was approved by Food and Drug Administration in April 2014. However, the efficacy of ceritinib in Asian patients have not been widely studied. Decrease of malignant pleural effusion (MPE) has been rarely reported after treatment with ceritinib. CASE DESCRIPTION: A 50-year old man diagnosed with stage IV lung adenocarcinoma presented with MPE and an ALK fusion gene mutation. The patient showed partial response to ceritinib after 2-month treatment. Ultrasound showed MPE significantly decreased. DISCUSSION AND EVALUATION: Ceritinib is a good choice, as a targeted therapy, which is more prospect in the advanced cancer patients than the traditional therapy. CONCLUSION: Ceritinib seems to have a good efficacy in reducing MPE in advanced Asian lung adenocarcinoma patients, when other chemotherapy failed. More... »

PAGES

2083

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s40064-016-3674-3

DOI

http://dx.doi.org/10.1186/s40064-016-3674-3

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1053162665

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/28018791


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Dongyang People's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.452237.5", 
          "name": [
            "Department of Medical Oncology, Dongyang People\u2019s Hospital, No. 60 West Wuning Road, 322100, Dongyang, Zhejiang, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wei", 
        "givenName": "Hangping", 
        "id": "sg:person.01134475251.29", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134475251.29"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dongyang People's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.452237.5", 
          "name": [
            "Department of Medical Oncology, Dongyang People\u2019s Hospital, No. 60 West Wuning Road, 322100, Dongyang, Zhejiang, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Du", 
        "givenName": "Fangming", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dongyang People's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.452237.5", 
          "name": [
            "Department of Medical Oncology, Dongyang People\u2019s Hospital, No. 60 West Wuning Road, 322100, Dongyang, Zhejiang, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lu", 
        "givenName": "Yifang", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dongyang People's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.452237.5", 
          "name": [
            "Department of Medical Oncology, Dongyang People\u2019s Hospital, No. 60 West Wuning Road, 322100, Dongyang, Zhejiang, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wei", 
        "givenName": "Juan", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Dongyang People's Hospital", 
          "id": "https://www.grid.ac/institutes/grid.452237.5", 
          "name": [
            "Department of Medical Oncology, Dongyang People\u2019s Hospital, No. 60 West Wuning Road, 322100, Dongyang, Zhejiang, People\u2019s Republic of China"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dong", 
        "givenName": "Xiaofang", 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1200/jco.2015.65.5936", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001727615"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1753465815597834", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002057506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1177/1753465815597834", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002057506"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1408440", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005474865"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1508887", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006442273"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1311107", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012182106"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/fon.14.94", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019645977"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-11-2906", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1019692765"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2012.02.001", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028704801"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1006448", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029333869"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000277", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030420839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0000000000000277", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1030420839"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1517/14656566.2012.688029", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032057023"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/fon.15.293", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033057328"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cllc.2013.04.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035450078"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-319-24932-2_2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045352424", 
          "https://doi.org/10.1007/978-3-319-24932-2_2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/978-3-319-24932-2_2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045352424", 
          "https://doi.org/10.1007/978-3-319-24932-2_2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/1471-2407-14-683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045895134", 
          "https://doi.org/10.1186/1471-2407-14-683"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/jto.0000000000000566", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045959397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1586/14737140.2016.1131612", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051850266"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa011954", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1052159806"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2016-12", 
    "datePublishedReg": "2016-12-01", 
    "description": "INTRODUCTION: Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor. It inhibits two of the most common ALK-mutants that confer resistance to crizotinib. Ceritinib was approved by Food and Drug Administration in April 2014. However, the efficacy of ceritinib in Asian patients have not been widely studied. Decrease of malignant pleural effusion (MPE) has been rarely reported after treatment with ceritinib.\nCASE DESCRIPTION: A 50-year old man diagnosed with stage IV lung adenocarcinoma presented with MPE and an ALK fusion gene mutation. The patient showed partial response to ceritinib after 2-month treatment. Ultrasound showed MPE significantly decreased.\nDISCUSSION AND EVALUATION: Ceritinib is a good choice, as a targeted therapy, which is more prospect in the advanced cancer patients than the traditional therapy.\nCONCLUSION: Ceritinib seems to have a good efficacy in reducing MPE in advanced Asian lung adenocarcinoma patients, when other chemotherapy failed.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1186/s40064-016-3674-3", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1047790", 
        "issn": [
          "2193-1801"
        ], 
        "name": "SpringerPlus", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "5"
      }
    ], 
    "name": "Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments", 
    "pagination": "2083", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "fd39e7481e734d4cd5b0cb51d6a3da9b586d47ecc704158def67007730c4c875"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "28018791"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "101597967"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s40064-016-3674-3"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1053162665"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s40064-016-3674-3", 
      "https://app.dimensions.ai/details/publication/pub.1053162665"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T12:36", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000363_0000000363/records_70031_00000002.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1186%2Fs40064-016-3674-3"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s40064-016-3674-3'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s40064-016-3674-3'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s40064-016-3674-3'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s40064-016-3674-3'


 

This table displays all metadata directly associated to this object as RDF triples.

148 TRIPLES      21 PREDICATES      47 URIs      21 LITERALS      9 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s40064-016-3674-3 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N314e1a0b33e64e1d82882fa766867188
4 schema:citation sg:pub.10.1007/978-3-319-24932-2_2
5 sg:pub.10.1186/1471-2407-14-683
6 https://doi.org/10.1016/j.cllc.2013.04.006
7 https://doi.org/10.1016/j.ejca.2012.02.001
8 https://doi.org/10.1056/nejmoa011954
9 https://doi.org/10.1056/nejmoa1006448
10 https://doi.org/10.1056/nejmoa1311107
11 https://doi.org/10.1056/nejmoa1408440
12 https://doi.org/10.1056/nejmoa1508887
13 https://doi.org/10.1097/cad.0000000000000277
14 https://doi.org/10.1097/jto.0000000000000566
15 https://doi.org/10.1158/1078-0432.ccr-11-2906
16 https://doi.org/10.1177/1753465815597834
17 https://doi.org/10.1200/jco.2015.65.5936
18 https://doi.org/10.1517/14656566.2012.688029
19 https://doi.org/10.1586/14737140.2016.1131612
20 https://doi.org/10.2217/fon.14.94
21 https://doi.org/10.2217/fon.15.293
22 schema:datePublished 2016-12
23 schema:datePublishedReg 2016-12-01
24 schema:description INTRODUCTION: Ceritinib is a second-generation anaplastic lymphoma kinase (ALK) inhibitor. It inhibits two of the most common ALK-mutants that confer resistance to crizotinib. Ceritinib was approved by Food and Drug Administration in April 2014. However, the efficacy of ceritinib in Asian patients have not been widely studied. Decrease of malignant pleural effusion (MPE) has been rarely reported after treatment with ceritinib. CASE DESCRIPTION: A 50-year old man diagnosed with stage IV lung adenocarcinoma presented with MPE and an ALK fusion gene mutation. The patient showed partial response to ceritinib after 2-month treatment. Ultrasound showed MPE significantly decreased. DISCUSSION AND EVALUATION: Ceritinib is a good choice, as a targeted therapy, which is more prospect in the advanced cancer patients than the traditional therapy. CONCLUSION: Ceritinib seems to have a good efficacy in reducing MPE in advanced Asian lung adenocarcinoma patients, when other chemotherapy failed.
25 schema:genre research_article
26 schema:inLanguage en
27 schema:isAccessibleForFree true
28 schema:isPartOf N4ad05fe3dd0c46fe878181eb54ba2cee
29 N51a7f08ec0864a518109606bbf904b24
30 sg:journal.1047790
31 schema:name Successful ceritinib treatment in a man with MPE and an ALK fusion gene mutation after multiple treatments
32 schema:pagination 2083
33 schema:productId N07ad55651f40476c816dc1eb5fbe330a
34 N2403ede0828a497693517dc6c8b3767b
35 N3eab65b638ce42a381c98467da0697e0
36 N694774e8be254f98949d718055185dee
37 Nd01365f77c8546c7af569d764a0258e3
38 schema:sameAs https://app.dimensions.ai/details/publication/pub.1053162665
39 https://doi.org/10.1186/s40064-016-3674-3
40 schema:sdDatePublished 2019-04-11T12:36
41 schema:sdLicense https://scigraph.springernature.com/explorer/license/
42 schema:sdPublisher N8e64e8e83c0441d299d27e2e287d4f70
43 schema:url https://link.springer.com/10.1186%2Fs40064-016-3674-3
44 sgo:license sg:explorer/license/
45 sgo:sdDataset articles
46 rdf:type schema:ScholarlyArticle
47 N05405a1bd4c94253a82f4102f53b3bb8 rdf:first Nb839752a5c8949db963b46b6549dd7c2
48 rdf:rest N2c32895c1f6b4965a9460e90177a4315
49 N06edf8222ccd44989c01150dd9f75d90 schema:affiliation https://www.grid.ac/institutes/grid.452237.5
50 schema:familyName Dong
51 schema:givenName Xiaofang
52 rdf:type schema:Person
53 N07ad55651f40476c816dc1eb5fbe330a schema:name nlm_unique_id
54 schema:value 101597967
55 rdf:type schema:PropertyValue
56 N2403ede0828a497693517dc6c8b3767b schema:name pubmed_id
57 schema:value 28018791
58 rdf:type schema:PropertyValue
59 N2c32895c1f6b4965a9460e90177a4315 rdf:first Na32d5e39f7644bd29885f54d6e85003f
60 rdf:rest N34ef66451a734b599d68888f5e166f18
61 N314e1a0b33e64e1d82882fa766867188 rdf:first sg:person.01134475251.29
62 rdf:rest N05405a1bd4c94253a82f4102f53b3bb8
63 N34ef66451a734b599d68888f5e166f18 rdf:first N4c0d867db5ae4f568e4021862c8777c2
64 rdf:rest Nb28c90e0c9194088a08400e00057c963
65 N3eab65b638ce42a381c98467da0697e0 schema:name doi
66 schema:value 10.1186/s40064-016-3674-3
67 rdf:type schema:PropertyValue
68 N4ad05fe3dd0c46fe878181eb54ba2cee schema:issueNumber 1
69 rdf:type schema:PublicationIssue
70 N4c0d867db5ae4f568e4021862c8777c2 schema:affiliation https://www.grid.ac/institutes/grid.452237.5
71 schema:familyName Wei
72 schema:givenName Juan
73 rdf:type schema:Person
74 N51a7f08ec0864a518109606bbf904b24 schema:volumeNumber 5
75 rdf:type schema:PublicationVolume
76 N694774e8be254f98949d718055185dee schema:name readcube_id
77 schema:value fd39e7481e734d4cd5b0cb51d6a3da9b586d47ecc704158def67007730c4c875
78 rdf:type schema:PropertyValue
79 N8e64e8e83c0441d299d27e2e287d4f70 schema:name Springer Nature - SN SciGraph project
80 rdf:type schema:Organization
81 Na32d5e39f7644bd29885f54d6e85003f schema:affiliation https://www.grid.ac/institutes/grid.452237.5
82 schema:familyName Lu
83 schema:givenName Yifang
84 rdf:type schema:Person
85 Nb28c90e0c9194088a08400e00057c963 rdf:first N06edf8222ccd44989c01150dd9f75d90
86 rdf:rest rdf:nil
87 Nb839752a5c8949db963b46b6549dd7c2 schema:affiliation https://www.grid.ac/institutes/grid.452237.5
88 schema:familyName Du
89 schema:givenName Fangming
90 rdf:type schema:Person
91 Nd01365f77c8546c7af569d764a0258e3 schema:name dimensions_id
92 schema:value pub.1053162665
93 rdf:type schema:PropertyValue
94 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
95 schema:name Medical and Health Sciences
96 rdf:type schema:DefinedTerm
97 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
98 schema:name Oncology and Carcinogenesis
99 rdf:type schema:DefinedTerm
100 sg:journal.1047790 schema:issn 2193-1801
101 schema:name SpringerPlus
102 rdf:type schema:Periodical
103 sg:person.01134475251.29 schema:affiliation https://www.grid.ac/institutes/grid.452237.5
104 schema:familyName Wei
105 schema:givenName Hangping
106 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01134475251.29
107 rdf:type schema:Person
108 sg:pub.10.1007/978-3-319-24932-2_2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045352424
109 https://doi.org/10.1007/978-3-319-24932-2_2
110 rdf:type schema:CreativeWork
111 sg:pub.10.1186/1471-2407-14-683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045895134
112 https://doi.org/10.1186/1471-2407-14-683
113 rdf:type schema:CreativeWork
114 https://doi.org/10.1016/j.cllc.2013.04.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035450078
115 rdf:type schema:CreativeWork
116 https://doi.org/10.1016/j.ejca.2012.02.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028704801
117 rdf:type schema:CreativeWork
118 https://doi.org/10.1056/nejmoa011954 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052159806
119 rdf:type schema:CreativeWork
120 https://doi.org/10.1056/nejmoa1006448 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029333869
121 rdf:type schema:CreativeWork
122 https://doi.org/10.1056/nejmoa1311107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012182106
123 rdf:type schema:CreativeWork
124 https://doi.org/10.1056/nejmoa1408440 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005474865
125 rdf:type schema:CreativeWork
126 https://doi.org/10.1056/nejmoa1508887 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006442273
127 rdf:type schema:CreativeWork
128 https://doi.org/10.1097/cad.0000000000000277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030420839
129 rdf:type schema:CreativeWork
130 https://doi.org/10.1097/jto.0000000000000566 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045959397
131 rdf:type schema:CreativeWork
132 https://doi.org/10.1158/1078-0432.ccr-11-2906 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019692765
133 rdf:type schema:CreativeWork
134 https://doi.org/10.1177/1753465815597834 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002057506
135 rdf:type schema:CreativeWork
136 https://doi.org/10.1200/jco.2015.65.5936 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001727615
137 rdf:type schema:CreativeWork
138 https://doi.org/10.1517/14656566.2012.688029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032057023
139 rdf:type schema:CreativeWork
140 https://doi.org/10.1586/14737140.2016.1131612 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051850266
141 rdf:type schema:CreativeWork
142 https://doi.org/10.2217/fon.14.94 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019645977
143 rdf:type schema:CreativeWork
144 https://doi.org/10.2217/fon.15.293 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033057328
145 rdf:type schema:CreativeWork
146 https://www.grid.ac/institutes/grid.452237.5 schema:alternateName Dongyang People's Hospital
147 schema:name Department of Medical Oncology, Dongyang People’s Hospital, No. 60 West Wuning Road, 322100, Dongyang, Zhejiang, People’s Republic of China
148 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...